Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis.

Lin Fan, Shuang Wu, Xingxing Xie, Yang Zheng, Longxia Chen, Ruilin Ding

Abstract readReview

In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lin Fan *Departments of Good Clinical Practice, Yaan People's Hospital, Yaan, Sichuan, China.

Shuang Wu *Department of Anesthesiology, Southwest Medical University, Luzhou, Sichuan, China.

Xingxing Xie *Departments of Pharmacy, Yaan People's Hospital, Yaan, Sichuan, China.

Yang ZhengDepartment of Clinical Research Management, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Longxia ChenDepartment of Clinical Research Management, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Ruilin DingDepartment of Clinical Research Management, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal stage of prostate cancer with poor prognosis. Clinical trials for mCRPC are growing rapidly worldwide. However, a comprehensive systematic analysis of the global research and development landscape in mCRPC remains lacking. Methods: This study queried the Trialtrove database for interventional trials in mCRPC registered between January 1, 2020 and March 27, 2026. After exclusion of unrelated trials and non-therapeutic studies, 474 trials were analyzed. Results: The therapeutic landscape for mCRPC has evolved into a highly diversified and dynamic field, overwhelmingly dominated by early-phase investigations. Targeted therapy, particularly PARP inhibitors, remain the leading class, while radiopharmaceutical therapy (RPT), centered on Conclusion: mCRPC clinical research landscape has diversified remarkably, shifting from conventional chemotherapy and endocrine therapy toward mechanism-based, biomarker-guided, and combination-oriented strategies.

Indexed as

clinical trialendocrine therapyimmunotherapylandscape analysismetastatic castration−resistant prostate cancerradiopharmaceutical therapy

Identifiers

PMID42877008

DOI10.3389/fonc.2026.1930401

PMCPMC13662642

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.